Key result
Mechanical circulatory support for end-stage heart failure improves quality of life and functional capacity, despite risks of cerebrovascular events, infection, and device malfunction.
Why the study?
Does mechanical circulatory support improve quality of life and functional capacity in patients with end-stage heart failure?
Does mechanical circulatory support improve quality of life and functional capacity in patients with end-stage heart failure?
Mechanical circulatory support serves as a definitive treatment option for end-stage heart failure that improves quality of life, though its widespread use is hindered by significant adverse event risks.
Supports MCS for quality-of-life gains in end-stage HF despite risks; leaves open need for randomized confirmation.
Mechanical circulatory support for end-stage heart failure has become routine and is now increasingly used as definitive treatment. Several small devices qualify for this purpose, but only a few have gained US Food and Drug Administration (FDA) approval as yet. Several studies, including the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) study, the Investigation of Non-transplant-Eligible Patients Who Are Inotrope Dependent (INTrEPID) and the HeartMate (HM) II trial have confirmed a significantly improved quality of life and functional capacity after device placement. However, cerebrovascular events, infection and device malfunction still pose a considerable risk to patients and hinder widespread use.
No takes yet. Share an insight, caveat, or question.
Ganslmeier et al. (2010) conducted a review in End-stage heart failure. Mechanical circulatory support was evaluated. Mechanical circulatory support for end-stage heart failure improves quality of life and functional capacity, despite risks of cerebrovascular events, infection, and device malfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: